VivoSeq
Other

IPF

1

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

IPF is an early-stage landscape with 1 program across 6 companies. The most active players are Boehringer Ingelheim, Global Blood Therapeutics, Sunshine Lake Pharma Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalG

Global Blood Therapeutics

0 programs

PreclinicalSunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalC

Contineum Therapeutics

0 programs

PreclinicalM

Modern Biosciences Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

AGMB-447

Agomab Spain S.L.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Terminated2 · 13%
Unknown status1 · 7%
Not yet recruiting1 · 7%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

15 trials

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Not yet recruiting·Sunshine Lake Pharma Co., Ltd. logoSunshine Lake Pharma Co., Ltd.·Phase 3·NCT07082842·472 enrolled
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT01136174·50 enrolled
Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT02579603·105 enrolled
SD, IL-13 Production Rate in IPF
Completed·Novartis logoNovartis·Phase 2·NCT00532233·52 enrolled
All-Case Surveillance of Ofev in Patients With IPF in Japan
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT02607722·10,117 enrolled
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT03242759·101 enrolled
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
Completed·CContineum Therapeutics·Phase 1·NCT06683612·16 enrolled
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Completed·GGlobal Blood Therapeutics·Phase 2·NCT02846324·39 enrolled
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT01417156·20 enrolled
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
Completed·GGeno LLC·Phase 2·NCT01265888·31 enrolled
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of Inhaled AGMB-447 in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
Completed·—·Phase 1·NCT06181370·143 enrolled
Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
Terminated·GGlobal Blood Therapeutics·Phase 2·NCT02989168·14 enrolled
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Terminated·IInterMune·Phase 3·NCT00076635·91 enrolled
A Study to Investigate Leramistat in Patients With IPF
Withdrawn·MModern Biosciences Ltd·Phase 2·NCT05951296
Phase ll Study of HEC585 in Patients With IPF
Unknown status·Sunshine Lake Pharma Co., Ltd. logoSunshine Lake Pharma Co., Ltd.·Phase 2·NCT05060822·270 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)